Skip to content

A Pilot Study on the Safety and Efficacy of LED Red Light at Different Energy Densities for Controlling Myopia Progression in Children and Adolescents

A Pilot Study on the Safety and Efficacy of LED Red Light at Different Energy Densities for Controlling Myopia Progression in Children and Adolescents

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600126612
Enrollment
Unknown
Registered
2026-06-12
Start date
2026-06-18
Completion date
Unknown
Last updated
2026-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia

Interventions

Red Light Group B:Prescription single-vision glasses combined with LED red light (4 J/cm2)
Red Light Group A:Prescription single-vision glasses combined with LED red light (2 J/cm2)
control group:Available only with single-vision lenses
Red Light Group D:Prescription single-vision glasses combined with LED red light (8J/cm2)
Red Light Group C:Prescription single-vision glasses combined with LED red light (6J/cm2)

Sponsors

Eye Hospital, Wenzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 12 Years

Inclusion criteria

Inclusion criteria: 1.Age 6 to 12 years at enrollment; gender is not restricted; 2.Individuals diagnosed with myopia according to the “Guidelines for the Prevention and Control of Myopia” issued by the General Office of the National Health Commission (Guo Wei Ban Yi Han [2024] No. 168); (i.e., when the eye is in a relaxed state, parallel lightpassing through the ocular refractive system and focusing in front of the retina is termed myopia; based on the equivalent spherical (SE) power measured after ciliary muscle paralysis, myopia is classified into three categories: low myopia, moderate myopia, and high myopia. Low myopia ranges from 50 to 300 diopters, moderate myopia ranges from 300 to 600 diopters, and high myopia exceeds 600 diopters); 3.Computerized refraction after bilateral ciliary muscle paralysis: -0.75D = SE < -5.00D; 4.Computerized refraction after bilateral cycloplegia with anisometropia SE < 1.5 D; 5.Computerized refraction after bilateral cycloplegia with bilateral cylindrical power = 2.50 D; 6.Best-corrected visual acuity in both eyes = 5.0; 7.Intraocular pressure in both eyes = 10 mmHg and = 21 mmHg; 8.No other organic lesions in either eye that affect visual acuity; 9.The subject and guardian understand the purpose of this trial and have signed the informed consent form; the subject is able to cooperate with treatment and related ophthalmic examinations, and will not take any myopia prevention or control measures other than those specified in the study protocol during the entire study period.

Exclusion criteria

Exclusion criteria: 1.Individuals diagnosed with manifest strabismus; 2.Congenital color vision deficiency (color blindness); 3.Any eye disease or ophthalmic surgery (including strabismus surgery) that may be associated with myopia or affect refractive development, as well as systemic or other conditions such as Marfan syndrome, retinopathy of prematurity, or diabetes; 4.Eye injuries or diseases of the cornea, conjunctiva, or eyelids (including keratoconus and herpetic keratitis), or retinal lesions, which the investigator assesses as likely to affect study results; 5.Use of any myopia control measures other than single-vision lenses within the past 3 months; 6.Having undergone binocular vision training or flip-card training within the past 1 month; 7.Photophobia or inability to open the eyes normally; 8.Any anatomical, skin, or other conditions that may interfere with the wearing of spectacles; 9.Participation in another clinical trial within 3 months prior to enrollment; 10.The subject has acute or chronic diseases (including other currently existing acute or chronic pain) or psychiatric disorders, etc., which may increase the risks associated with study participation or the use of the investigational product, or may affect the interpretation of study results, and which, in the judgment of the investigator or a designated medically qualified person, render the subject unsuitable for enrollment in this study;

Design outcomes

Primary

MeasureTime frame
Change in axial length from baseline;

Secondary

MeasureTime frame
Equipment defect rate;Change in axial length from baseline;Pathological changes in fundus photography;Choroidal Thickness Measurement;Equivalent spherical power;Incidence of adverse events;Best-corrected visual acuity;Morphological Structure of the Retinal Layers on OCT;

Countries

China

Contacts

Public ContactJie Chen

Eye Hospital, Wenzhou Medical University

cjie@sunyopt.edu+86 577 8806 8817

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 21, 2026